Skip to Content

Fewer doses of HPV vaccine result in immune response similar to three-dose regimen

Posted on November 04, 2013

NCI scientists report that two doses of a human papillomavirus (HPV) vaccine, trademarked as Cervarix, resulted in similar serum antibody levels against two of the most carcinogenic types of HPV (16 and 18), compared to a standard three dose regimen. The results appeared in the November 2013 issue of Cancer Prevention Research.

News

NCI Press Release: Fewer doses of HPV vaccine result in immune response similar to three-dose regimen
The National Cancer Institute (NCI) press note for the study

Information for Journalists

To request an interview with a DCEG investigator, contact the NCI Office of Media Relations:

E-mail:
ncipressofficers@
mail.nih.gov

Phone: 301-496-6641